Anika Therapeutics Inc: Highlights
Financial data in U.S. dollars
| Financial Highlights |
|---|
| Sales |
38.48 Mil |
| Income |
4.07 Mil |
| Net Profit Margin |
10.62% |
| Return on Equity |
6.59% |
| Debt/Equity Ratio |
0.23 |
|
| Revenue/Share |
3.34 |
| Earnings/Share |
0.35 |
| Book Value/Share |
5.62 |
| Dividend Rate |
0.00 |
| Payout Ratio |
0.00% |
|
| Revenue - Quarterly Results (in Millions) |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | 9.2 | 8.5 | 6.1 |
| 2nd Qtr | 9.5 | 9.1 | 7.1 |
| 3rd Qtr | 10.8 | 9.2 | 8.0 |
| 4th Qtr | NA | 9.0 | 9.6 |
| Total | 29.5 | 35.8 | 30.8 |
| Earnings Per Share - Quarterly Results |
|---|
| | FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | $0.05 | $0.05 | $0.11 |
| 2nd Qtr | $0.08 | $0.07 | $0.12 |
| 3rd Qtr | $0.13 | $0.10 | $0.16 |
| 4th Qtr | NA | $0.10 | $0.15 |
| Total | $0.26 | $0.32 | $0.54 |
| Qtr. over Qtr. EPS Growth Rate |
| FY (12/09) | FY (12/08) | FY (12/07) |
|---|
| 1st Qtr | -50% | -67% | --- |
| 2nd Qtr | 60% | 40% | 9% |
| 3rd Qtr | 62% | 43% | 33% |
| 4th Qtr | NA | 0% | -6% |
| Yr. over Yr. EPS Growth Rate |
| FY (12/09) | FY (12/08) |
|---|
| 1st Qtr | 0% | -55% |
| 2nd Qtr | 14% | -42% |
| 3rd Qtr | 30% | -37% |
| 4th Qtr | NA | -33% |
advertisement
Recent News